In short
This article discusses ongoing clinical trials investigating the use of M-(18F)-Fluorobenzylguanidine ([18F]mFBG) in PET-CT imaging for patients with pheochromocytoma, a rare type of adrenal gland tumor. The trials aim to assess the effectiveness of this innovative imaging technique in detecting pheochromocytoma lesions compared to conventional CT scans, as well as evaluate its safety and optimal timing for imaging.
At a glance
- Drug Name
- M-(18F)-Fluorobenzylguanidine ([18F]mFBG)
- Administration
- Intravenous injection, maximum 2 MBq/kg
- Target Condition
- Pheochromocytoma (adrenal gland tumor)
- Primary Objective
- Compare lesion detection by [18F]mFBG PET-CT vs. conventional CT
- Secondary Objectives
- Optimal imaging time, correlation with pathology, radiation dose estimation, safety analysis
- Key Inclusion Criteria
- Age ≥18, diagnosed/suspected pheochromocytoma, planned surgery, recent CT scan
- Key Exclusion Criteria
- Pregnancy, lactation, uncontrolled infections, inability to undergo PET-CT or surgery
What is M-(18F)-FLUOROBENZYLGUANIDINE?
M-(18F)-FLUOROBENZYLGUANIDINE, also known as [18F]mFBG, is a new imaging agent being studied for its potential in detecting and visualizing a rare type of tumor called pheochromocytoma. This compound is a solution for injection and is being developed to improve the way doctors can see and diagnose these tumors using a special type of scan called PET-CT (Positron Emission Tomography-Computed Tomography).
The drug is also known by several other names, including:
- [18F]meta-fluorobenzylguanidine
- [18F]mFBG
- Florbenguane (18F)
- IRP-101
Understanding Pheochromocytoma
Pheochromocytoma is a rare type of tumor that develops in the adrenal glands, which are small glands located on top of your kidneys. These tumors can produce excess hormones called catecholamines, which can cause high blood pressure, rapid heartbeat, and other symptoms. Accurate diagnosis and localization of these tumors are crucial for proper treatment.
How M-(18F)-FLUOROBENZYLGUANIDINE Works
M-(18F)-FLUOROBENZYLGUANIDINE is designed to be injected into the patient's bloodstream. Once in the body, it travels to areas where pheochromocytoma tumors might be present. The compound is specially crafted to be taken up by these tumor cells.
When the patient undergoes a PET-CT scan, the M-(18F)-FLUOROBENZYLGUANIDINE lights up in areas where the tumors are located, allowing doctors to see them more clearly than with conventional CT scans alone. This could potentially lead to more accurate diagnosis and better treatment planning.
Current Clinical Trial
A clinical trial is currently underway to study the effectiveness of M-(18F)-FLUOROBENZYLGUANIDINE in imaging pheochromocytoma. The main goal of this study is to compare how well [18F]mFBG PET-CT can detect pheochromocytoma lesions compared to conventional CT scans.
The study aims to answer several important questions:
- How many tumor lesions can [18F]mFBG PET-CT detect compared to regular CT scans?
- What is the best timing for taking the [18F]mFBG PET-CT images after injection?
- How well do the PET-CT findings match up with what doctors see when they examine the tumor tissue under a microscope?
- How much radiation does the body absorb from [18F]mFBG?
- Is [18F]mFBG safe to use in patients?
Potential Benefits of M-(18F)-FLUOROBENZYLGUANIDINE
If successful, M-(18F)-FLUOROBENZYLGUANIDINE could offer several benefits for patients with pheochromocytoma:
- More accurate detection of tumor lesions, potentially catching tumors that might be missed by conventional CT scans
- Better understanding of the extent of the disease, which could help in planning surgery or other treatments
- Improved ability to monitor the disease over time
- Potential for earlier diagnosis, which could lead to better outcomes for patients
Safety Considerations
As with any new medical treatment or diagnostic tool, safety is a top priority. The clinical trial is designed to carefully monitor any side effects or adverse events that might occur after administration of M-(18F)-FLUOROBENZYLGUANIDINE. The researchers will be looking closely at how patients react to the injection and if there are any unexpected effects.
It's important to note that this compound contains a small amount of radioactive material (the "18F" part of the name), which is necessary for the PET-CT imaging to work. The study will measure how much radiation patients are exposed to, to ensure it stays within safe limits.
Who Can Participate in the Study?
The study has specific criteria for who can participate. These include:
- Patients who are 18 years or older
- Patients diagnosed with pheochromocytoma or have lab results suggesting they might have it
- Patients who are scheduled for surgery to remove the tumor
- Patients who have had a CT scan within the last 8 weeks
- Patients who are in relatively good overall health (ECOG status of 0-2, which means they are able to carry out most daily activities)
Some factors that would prevent a person from participating include:
- Being pregnant or breastfeeding
- Having active, serious infections not controlled by antibiotics
- Being unable or unwilling to undergo PET-CT scanning or surgery
- Having received treatment that might interfere with the study between the conventional CT scan and the [18F]mFBG PET-CT
This clinical trial represents an important step in improving how we diagnose and understand pheochromocytoma. If successful, M-(18F)-FLUOROBENZYLGUANIDINE could become a valuable tool in the fight against this rare but serious condition.